Pharmaceutical Technology

DECEMBER 25, 2023

Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.

52

52

Pharmaceutical Technology

DECEMBER 6, 2023

XmAb-662 is under clinical development by Xencor and currently in Phase I for Cervical Cancer.

52

52

The Checkup by Singlecare

JANUARY 12, 2024

Treatment of spotting before a period may include watching and waiting, hormonal treatments, medications to reduce menstrual bleeding, and surgeries to remove cervical polyps or fibroids. Cervical polyps “Spotting before your period, and especially after vaginal intercourse, is often caused by a cervical polyp,” says Dr. Hamburger.

Mayo Clinic 52

Mayo Clinic 52

Pharmaceutical Technology

JANUARY 4, 2024

XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

DECEMBER 20, 2023

VTP-200 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Cervical Cancer.

40

40

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front. Prior success.

Vaccines 134

Vaccines Immunization Compounding Pharmaceutical Companies 134

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Cervical Cancer.

40

40

The Checkup by Singlecare

NOVEMBER 14, 2023

Cervical polyps Cervical polyps are small, benign growths found on your cervix. About 2% to 5% of women experience them, according to the Cleveland Clinic , and they are a common cause of mid-cycle bleeding. Cervical cancer screening should begin at age 21.

Hospitals 52

Hospitals Vaccines 52

Pharmaceutical Technology

NOVEMBER 5, 2023

XB-002 is under clinical development by Exelixis and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

JULY 7, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).

40

40

Pharmaceutical Technology

JULY 7, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).

40

40

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on DARPin technology.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

JUNE 27, 2022

Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of studies conducted in the past 15 years. Figure 1: Ethnic composition of cancer clinical trial cohorts in the USA.

FDA 110

FDA 110

European Pharmaceutical Review

JULY 27, 2023

ENHERTU ® (trastuzumab deruxtecan) has demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial. These cancers include biliary tract, bladder, cervical, endometrial, ovarian and pancreatic.

90

90

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

52

52

pharmaphorum

OCTOBER 14, 2021

The FDA has approved Merck’s Keytruda as a first-line therapy for advanced cervical cancer. Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1.

Chemotherapy 45

Chemotherapy Research Laboratories Immunization FDA 45

Pharmaceutical Technology

FEBRUARY 19, 2023

Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

40

40

Pharmaceutical Technology

MARCH 23, 2023

Adcetris is currently active in multiple clinical trials, including the ECHELON-3 Phase lll study for patients with relapsed or refractory diffuse large B-cell lymphoma. It is indicated for adults with metastatic cervical cancer as a second-line therapeutic.

Chemotherapy 59

Chemotherapy Compounding FDA 59

PharmaShots

JUNE 15, 2023

In Nov 2021, the clinical results showed that TIL cell therapy + pembrolizumab in immune-checkpoint inhibitor naïve patients showed ORR (57%) in Cervical Cancer, 60% in Melanoma with 30% CR & 39% in Head & Neck Cancer The Iovance TIL platform showed promising clinical data across multiple solid tumors.

Immunization 40

Immunization FDA 40

PharmaShots

JUNE 2, 2023

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

FDA 40

FDA 40

pharmaphorum

AUGUST 22, 2021

The move comes amid reports that some people are being offered RAS for the prevention or treatment of breast cancer, sometimes as part of a clinical trial, even though many of the studies are being undertaken “without the FDA oversight required.”

FDA 93

FDA 93

Pharmafile

MARCH 21, 2023

read more

Immunization 52

Immunization 52

The Checkup by Singlecare

OCTOBER 12, 2023

Just as breast exams and mammograms can detect breast cancer, pelvic exams and Pap smears can help identify problems with your reproductive organs. When a pap smear is needed a brush or plastic spatula is used to collect cells to check for cancerous cells. Gloved fingers can be used to assess the cervix, uterus, and ovaries.

Mayo Clinic 105

Mayo Clinic Vaccines 105

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It also has pre-clinical research and development to extend its product development.

40

40

The Checkup by Singlecare

JANUARY 12, 2024

However, there are a few other less common reasons you may bleed during intercourse, like cervical polyps (which are typically benign cervical growths), precancerous cervical changes, or cervical cancer. Miller says intercourse can cause injury to the vaginal tissue. How long does pink discharge last?

Mayo Clinic 52

Mayo Clinic Hospitals 52

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.

40

40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.

40

40

pharmaphorum

MARCH 30, 2022

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in combination cancer immunotherapy. The post Roche hit by failure of TIGIT drug tiragolumab in lung cancer appeared first on.

Chemotherapy 97

Chemotherapy Immunization FDA 97

The Checkup by Singlecare

OCTOBER 23, 2023

A menstrual cycle can range between 21 days in length to 35 days , while actual bleeding might last anywhere from two to seven days , according to the Mayo Clinic. The color of your period blood changes, depending on the time in your cycle or the presence of other fluids that mix with the blood, such as cervical mucus.

Mayo Clinic 105

Mayo Clinic 105

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

MARCH 22, 2021

million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers. But it was cancer that the German biotech originally targeted with the technology, which is capable of converting cells into “drug factories” to fight a range of diseases.

Vaccines 75

Vaccines 75

Pharmaceutical Technology

AUGUST 19, 2022

The European Commission (EC) has granted approval for Celltrion Healthcare ’s Vegzelma (CT-P16) to treat metastatic breast cancer, advanced and/or metastatic renal cell cancer, non-small cell lung cancer, ovarian cancer, metastatic carcinoma of the colon or rectum and cervical cancer.

FDA 52

FDA 52

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is a triazolopyrazine derivative. Abion is headquartered in Seoul City, Seoul, South Korea.

40

40

Pharmaceutical Technology

FEBRUARY 26, 2023

Cellular Immunotherapy for Non-Small Cell Lung Cancer is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Buy the report here.

Immunization 40

Immunization 40

Roots Analysis

OCTOBER 4, 2023

In addition to approved therapies, I would like to mention that in terms of clinical development, the current pipeline of bispecific antibody therapeutics looks promising. Further, it is worth mentioning that over 45% of these drug candidates are being evaluated under phase I clinical studies. during the period 2023-2035.

Chemotherapy 40

Chemotherapy Immunization FDA 40

Pharmaceutical Technology

MAY 31, 2023

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines 40

Pharmaceutical Technology

FEBRUARY 19, 2023

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy 40